LNTH Lantheus Holdings Inc.

18.72
-0.2  -1%
Previous Close 18.91
Open 18.75
Price To Book 7.26
Market Cap 734,724,282
Shares 39,248,092
Volume 454,548
Short Ratio
Av. Daily Volume 388,719
Stock charts supplied by TradingView

NewsSee all news

  1. Lantheus Holdings Announces Senior Leadership Appointment

    Company Appoints Istvan Molnar, M.D. as Chief Medical Officer Lantheus Holdings, Inc. (NASDAQ:LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and

  2. Lantheus Enters into Strategic Collaboration with CarThera for Use of Microbubbles in Combination with SonoCloud® System for Treatment of Glioblastoma

    Agreement Supports Lantheus' Microbubble Franchise Growth Strategy and Expansion into Oncology Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global

  3. Lantheus Holdings to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging

  4. Lantheus Releases Comprehensive Strategic Plan for Progenics

    Lantheus' Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus' In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the

  5. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be completed 2H 2020.
flurpiridaz F 18
Coronary artery disease (CAD)

Latest News

  1. Lantheus Holdings Announces Senior Leadership Appointment

    Company Appoints Istvan Molnar, M.D. as Chief Medical Officer Lantheus Holdings, Inc. (NASDAQ:LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and

  2. Lantheus Enters into Strategic Collaboration with CarThera for Use of Microbubbles in Combination with SonoCloud® System for Treatment of Glioblastoma

    Agreement Supports Lantheus' Microbubble Franchise Growth Strategy and Expansion into Oncology Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global

  3. Lantheus Holdings to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging

  4. Lantheus Releases Comprehensive Strategic Plan for Progenics

    Lantheus' Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus' In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the

  5. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  6. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  7. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  8. Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by

  9. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  10. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  11. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  12. Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They

  13. PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to Lantheus

  14. Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

    Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus' Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the

  15. Lantheus Holdings to Present at the Wells Fargo Securities 2019 Healthcare Conference

    Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging